ID   UM-UC-3
AC   CVCL_1783
SY   UMUC-3; UM-UC3; UMUC3; UC-3; University of Michigan-Urothelial Carcinoma-3
DR   BTO; BTO:0003723
DR   CLO; CLO_0009487
DR   EFO; EFO_0006771
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1749
DR   BioGRID_ORCS_Cell_line; 444
DR   BioSample; SAMN03471418
DR   BioSample; SAMN03473229
DR   BioSample; SAMN10987601
DR   cancercelllines; CVCL_1783
DR   CCRID; 3101HUMTCHu217
DR   Cell_Model_Passport; SIDM01182
DR   ChEMBL-Cells; CHEMBL3307245
DR   ChEMBL-Targets; CHEMBL612799
DR   CLS; 305074
DR   Cosmic; 715827
DR   Cosmic; 724838
DR   Cosmic; 760478
DR   Cosmic; 845568
DR   Cosmic; 846273
DR   Cosmic; 928818
DR   Cosmic; 943744
DR   Cosmic; 1046684
DR   Cosmic; 1082647
DR   Cosmic; 1285132
DR   Cosmic; 1285995
DR   Cosmic; 1302358
DR   Cosmic; 1927294
DR   Cosmic; 1938480
DR   Cosmic; 1938700
DR   Cosmic; 2050468
DR   Cosmic; 2057446
DR   Cosmic; 2212694
DR   Cosmic; 2444238
DR   Cosmic; 2700982
DR   Cosmic-CLP; 724838
DR   DepMap; ACH-000522
DR   ECACC; 96020936
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 724838
DR   GEO; GSM136234
DR   GEO; GSM887729
DR   GEO; GSM888824
DR   GEO; GSM1374978
DR   GEO; GSM1574568
DR   GEO; GSM1670567
DR   IARC_TP53; 377
DR   IGRhCellID; UMUC3
DR   KCB; KCB 2014053YJ
DR   LiGeA; CCLE_492
DR   LINCS_LDP; LCL-1721
DR   PharmacoDB; UMUC3_1643_2019
DR   PRIDE; PXD003105
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1783
DR   PubChem_Cell_line; CVCL_1783
DR   Wikidata; Q54990989
RX   PubMed=3761468;
RX   PubMed=7787250;
RX   PubMed=8873383;
RX   PubMed=9850064;
RX   PubMed=11921286;
RX   PubMed=12068308;
RX   PubMed=12127398;
RX   PubMed=15846775;
RX   PubMed=16469639;
RX   PubMed=18812553;
RX   PubMed=19375735;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25997541;
RX   PubMed=26589293;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27270441;
RX   PubMed=27397505;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=3761468).
CC   HLA typing: A*02:01,33:01; B*07:02,14:02; C*07:02,07:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (PubMed=20215515).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; Cosmic-CLP; DepMap).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.66%; Native American=0%; East Asian, North=3.71%; East Asian, South=0%; South Asian=0%; European, North=55.69%; European, South=36.94% (PubMed=30894373).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): ATCC; Cosmic-CLP; ECACC; PubMed=25877200; PubMed=27270441
ST   Amelogenin: X
ST   CSF1PO: 10 (ECACC; PubMed=25877200; PubMed=27270441)
ST   CSF1PO: 10,11 (ATCC; Cosmic-CLP)
ST   D13S317: 8
ST   D16S539: 8,9
ST   D18S51: 14
ST   D21S11: 31
ST   D3S1358: 17,18
ST   D5S818: 12
ST   D7S820: 8,9 (ATCC; Cosmic-CLP; ECACC; PubMed=25877200)
ST   D7S820: 9 (PubMed=27270441)
ST   D8S1179: 13
ST   FGA: 20,21
ST   Penta D: 13
ST   Penta E: 12
ST   TH01: 6,9
ST   TPOX: 10
ST   vWA: 17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   PubMed=3761468; DOI=10.1016/S0022-5347(17)45139-1;
RA   Grossman H.B., Wedemeyer G., Ren L.-Q., Wilson G.N., Cox B.;
RT   "Improved growth of human urothelial carcinoma cell cultures.";
RL   J. Urol. 136:953-959(1986).
//
RX   PubMed=7787250;
RA   Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J.,
RA   Lippa M., Hatzivassiliou G., Tan J.;
RT   "p53 mutations in bladder carcinoma cell lines.";
RL   Oncol. Res. 6:569-579(1994).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
//
RX   PubMed=11921286; DOI=10.1002/gcc.10050;
RA   Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N.,
RA   Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.;
RT   "Molecular genetic analysis of chromosome 9 candidate tumor-suppressor
RT   loci in bladder cancer cell lines.";
RL   Genes Chromosomes Cancer 34:86-96(2002).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3;
RA   Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E.,
RA   Young B.D., Oliver R.T.D.;
RT   "Novel chromosome findings in bladder cancer cell lines detected with
RT   multiplex fluorescence in situ hybridization.";
RL   Cancer Genet. Cytogenet. 135:139-146(2002).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=16469639; DOI=10.1016/S0022-5347(05)00323-X;
RA   Sabichi A.L., Keyhani A., Tanaka N., Delacerda J., Lee I.-L., Zou C.-P.,
RA   Zhou J.-H., Benedict W.F., Grossman H.B.;
RT   "Characterization of a panel of cell lines derived from urothelial
RT   neoplasms: genetic alterations, growth in vivo and the relationship of
RT   adenoviral mediated gene transfer to coxsackie adenovirus receptor
RT   expression.";
RL   J. Urol. 175:1133-1137(2006).
//
RX   PubMed=18812553; DOI=10.1093/jnci/djn304;
RA   Park H.-S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S.,
RA   Spiess P.E., Steinberg J.R., Wang Z., Katz R.L., Dinney C.P.N.,
RA   Elias K.J., Lotan Y., Naeem R.C., Baggerly K., Sen S., Grossman H.B.,
RA   Czerniak B.;
RT   "Quantitation of Aurora kinase A gene copy number in urine sediments
RT   and bladder cancer detection.";
RL   J. Natl. Cancer Inst. 100:1401-1411(2008).
//
RX   PubMed=19375735; DOI=10.1016/j.juro.2009.01.108;
RA   Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.;
RT   "The use of short tandem repeat profiling to characterize human
RT   bladder cancer cell lines.";
RL   J. Urol. 181:2737-2748(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//